27 August 2003
Med Sci Monit 2003; 9(8): CS80-87 :: ID: 13109
Background:Severe sepsis is a disease associated with high mortality rates, which may be related to late diagnosis and institution of treatment, as well as unsatisfactory effectiveness of therapies used so far. Frequent monitoring of the patient’s clinical condition and laboratory results for early signs of sepsis and use of recombinant activated protein C can improve significantly the outcome of treatment.Case Report:The paper presents two patients with severe sepsis treated with drotrecogin alfa (activated). The first one, after multiorgan trauma, with renal failure due to crush injury, started to manifest gradually progressing symptoms of severe sepsis on 9th day of hospitalization in ICU. On 18th day, developing septic shock was diagnosed. As the initial standard therapy proved ineffective, it was decided to start recombinant human activated protein C (rhAPC). During infusion of the drug, dynamic improvement of organ function (respiratory and circulatory system, kidneys) and general condition of the patient was observed. The second patient, with rapidly progressing symptoms of septic shock and liver abscess confirmed as the source of infection, was subjected to therapy with Xigris® (Eli Lilly, USA) on the 2nd day of treatment in ICU, 12 hours after abscess drainage and compensation of blood platelet deficiency. This case also demonstrated rapid improvement of the patient’s condition and function of the organs involved by the disease (rapid stabilization of blood platelet count is notable).Conclusions:In both presented cases, the therapy with drotrecogin alfa (activated) was used due to lack of satisfactory response to initial standard treatment. Both cases indicate that the preparation is effective and safe.
Keywords: Anti-Infective Agents - therapeutic use, Multiple Organ Failure - drug therapy, Protein C - therapeutic use, Radiography, Thoracic, Recombinant Proteins - therapeutic use, Sepsis - drug therapy, Sepsis - mortality
01 February 2023 : EditorialEditorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
Med Sci Monit 2023; 29:e939580
19 January 2023 : Clinical ResearchEvaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...
Med Sci Monit In Press; DOI: 10.12659/MSM.938892
19 January 2023 : Clinical ResearchDetermining the Impact of the COVID-19 Pandemic on Dental Care in the Serbian Adult Population: An Online Q...
Med Sci Monit 2023; 29:e939238
27 December 2022 : Clinical ResearchEffect of Physiotherapy to Correct Rounded Shoulder Posture in 30 Patients During the COVID-19 Pandemic in ...
Med Sci Monit 2022; 28:e938926
03 Feb 2023 : Clinical ResearchTreatment of Gingival Recession Defects with Pouch and Tunnel Technique Using Connective Tissue Graft and L...
Med Sci Monit In Press; DOI: 10.12659/MSM.938865
02 Feb 2023 : Clinical ResearchOnline Questionnaire-Based Study to Evaluate the Attitudes and Use of Rubber Dental Dams by Saudi Dental Pr...
Med Sci Monit In Press; DOI: 10.12659/MSM.938672
02 Feb 2023 : Database AnalysisPrognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based...
Med Sci Monit In Press; DOI: 10.12659/MSM.938785
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292